Third Joint Conference of the British HIV Association (BHIVA)

with the

British Association for Sexual Health and HIV (BASHH)

1–4 April 2014

Arena and Convention Centre Liverpool
# Report

## HIV treatment, so far so good... can we do better?

**Date of preparation:** March 2014

**HIV_Report01.indd   17/03/2014   16:12**

### Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 09:00-09:05 | Welcome and introductions  
Chair: Dr Mark Nelson, Chelsea and Westminster Hospital |
| 09:05-09:25 | A solid start  
Dr Nicola Mackie, St Mary’s Hospital, London |
| 09:25-09:50 | Could do better  
Dr Laura Waters, Mortimer Market Centre, London |
| 09:50-10:00 | Question time and meeting close |

---

**Comments**

Great work to date! Looking forward to renewed efforts next term...
Liverpool · 2014

CONTENTS AND LOCATIONS

BHIVA & BASHH Committees ................................................................. 4
Programme Summary ........................................................................... 5
Programme ............................................................................................ 6–18
Satellite Symposia, Seminars and Workshops ...................................... 20–25
Exhibition Floor Plan and Exhibitors .................................................... 26
Conference Information ..................................................................... 27,28
Conference Scholarships and Awards ................................................ 29
Social Events ......................................................................................... 30
BHIVA / BASHH Plenary Speakers, Biographies .................................. 32–36
Sponsors and Exhibitors ....................................................................... 38

Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and dining areas

VENUES AND LOCATIONS

All locations are Arena and Convention Centre Liverpool, unless stated otherwise

Registration ............................................................................................. Galleria Foyer, Lower Level
Lecture Theatre ...................................................................................... Hall 1A, Upper Level
Exhibition ............................................................................................... Hall 2, Lower Level
Posters .................................................................................................... Hall 2, Lower Level
Lunch and Refreshments ..................................................................... Hall 2, Lower Level
BHIVA / BASHH Lunchtime Workshops ............................................... See pages 6–18 for further details
Satellite Symposia ................................................................................ Hall 1A, Upper Level
Sponsors’ Workshops .......................................................................... See pages 20–25 for further details
Speakers’ Preview Room ...................................................................... Room 10, Upper Level
Sponsors’ Rehearsal Room .................................................................. Room 9, Upper Level
Welcome Reception ............................................................................. Speeches: Hall 1A, Upper Level
.......................................................... Reception: Hall 2, Lower Level
Civic Reception ...................................................................................... Matou Restaurant
Gala Dinner ............................................................................................ St George’s Hall

18 CPD Credits  Unique reference number: 87191
BHIVA & BASHH COMMITTEES

BHIVA / BASHH JOINT CONFERENCES COMMITTEE (JCC)

Dr David Asboe  
BHIVA Chair

Mr Garry Brough  
BHIVA / BASHH Community Representative

Dr Annemiek de Ruiter  
BHIVA Secretary

Dr Elizabeth Foley  
BASHH Invited Representative

Dr Mark Lawton  
Local Host

Professor Clifford Leen  
BHIVA Treasurer

Dr Alastair Miller  
Local Host

Dr Mark Nelson  
BHIVA Education and Scientific Subcommittee Chair

Dr Adrian Palfreeman  
BHIVA Vice Chair

Dr Daniel Richardson  
BASHH Conferences Secretary

Prof Jonathan Ross  
BASHH Treasurer

Dr Laura Waters  
BASHH Invited Representative

Dr John White  
BASHH Invited Representative

ORAL RESEARCH JUDGING PANEL

Dr Annemiek de Ruiter (Co-chair)  
St Thomas’ Hospital, London

Dr Mette Rodgers (Co-chair)  
Croydon University Hospital

Mr Garry Brough  
UK Community Advisory Board (UK-CAB)

Dr Mas Chaponda  
Royal Liverpool University Hospital

Dr Lucy Dorrell  
University of Oxford

Dr Olamide Dosekun  
Imperial College Healthcare NHS Trust, London

Dr Emma Fox  
Kent Community Health NHS Trust

Dr Babu Kulasegaram  
St Thomas’ Hospital, London

Dr Leena Sathia  
Royal Free Hampstead NHS Trust, London

Dr John Sweeney  
Blackpool Sexual Health Services

Dr Alan Tang  
Royal Berkshire NHS Foundation Trust, Reading

Dr Melinda Tenant-Flowers  
King’s College Hospital NHS Foundation Trust

POSTER PRESENTATION JUDGING PANEL

Dr Carol Emerson (Co-chair)  
The Royal Hospitals, Belfast

Dr Danielle Mercey (Co-chair)  
Central & North West London NHS Foundation Trust

Dr Sophie Brady  
Bradford Teaching Hospitals NHS Trust

Dr Elizabeth Carlin  
Nottingham University Hospitals NHS Trust

Dr John Evans-Jones  
The Countess of Chester Hospital NHS Trust

Professor Anna Maria Geretti  
University of Liverpool

Dr David Goldmeier  
Imperial College Healthcare NHS Trust, London

Dr Margaret Kingston  
Central Manchester University Hospitals NHS Foundation Trust

Dr Teena Mathew  
Royal Liverpool University Hospital

Ms Sheila Morris  
Western General Hospital, Edinburgh

Dr Chloe Orkin  
Barts Health NHS Trust, London

Dr Andrew Riordan  
Alder Hey Children’s NHS Foundation Trust

Professor Caroline Sabin  
University College London

Dr Nicola Steedman  
Scottish Executive

Dr Ann Sullivan  
Chelsea and Westminster Hospital, London

Dr Craig Tipple  
Imperial College Healthcare NHS Trust, London

BHIVA EXECUTIVE COMMITTEE

Chair
Dr D Asboe  
Chelsea and Westminster Hospital, London

Vice Chair
Dr AJ Palfreeman  
Leicester Royal Infirmary

Honorary Secretary
Dr A de Ruiter  
St Thomas’ Hospital, London

Honorary Treasurer
Prof C Leen  
Western General Hospital, Edinburgh

TRUSTEES

Dr B Angus  
University of Oxford

Prof M Bower  
Chelsea and Westminster Hospital, London

Mr G Brough  
UK Community Advisory Board

Dr M Chaponda  
Royal Liverpool University Hospital

Dr D Churchill  
Royal Sussex County Hospital, Brighton

Dr L Dorrell  
University of Oxford

Prof MJ Fisher  
Brighton and Sussex University Hospitals NHS Trust

Dr AR Freedman  
Cardiff University School of Medicine

Prof BG Gazzard  
Chelsea and Westminster Hospital, London

Dr RB Kulasegaram  
St Thomas’ Hospital, London

Dr A Miller  
Royal Liverpool University Hospital

Ms S Morris  
Western General Hospital, Edinburgh

Dr MR Nelson  
Chelsea and Westminster Hospital, London

Prof C Sabin  
University College London

Dr A Sullivan  
Chelsea and Westminster Hospital, London

Dr M Tenant-Flowers  
King’s College Hospital NHS Foundation Trust

BASHH BOARD

President
Dr Jan Clarke  
Leeds Teaching Hospitals NHS Trust

Vice President
Dr Elizabeth Carlin  
Nottingham University Hospitals NHS Trust

Treasurer
Prof Jonathan Ross  
University Hospitals Birmingham NHS Trust

General Secretary
Dr Elizabeth Foley

TRUSTEES

Dr Alan Tang  
Royal Berkshire NHS Foundation Trust, Reading

Dr Daniel Richardson  
Brighton & Sussex University Hospitals NHS Trust

Dr Liat Sarner  
Barts Health NHS Trust, London

Dr Cecilia Priestly  
Dorset County Hospital NHS Foundation Trust

Dr Jillian Pritchard  
Ashford and St Peter’s Hospitals NHS Trust, Surrey

Dr Sris Allan  
Coventry and Warwickshire Hospital

Dr Nneka Nwokolo  
Chelsea and Westminster Hospital, London

Dr Alan McOwan  
Chelsea and Westminster Hospital, London

Mr David Roberts-Jones  
Lay Trustee

Dr Emily Lord  
Churchill Hospital, Oxford

Ms Ceri Evans  
Chelsea and Westminster Hospital, London

Mr Colin Roberts  
Chelsea and Westminster Hospital, London

Dr John Lee  
King Street Health Centre, Wakefield

Mr Peter Greenhouse  
United Hospitals Bristol NHS Foundation Trust

Dr Immy Ahmed  
Nottingham University Hospitals NHS Trust

Dr Martyn Wood  
Mid Cheshire Hospitals NHS Foundation Trust

Dr Janet Wilson  
Leeds Teaching Hospitals NHS Trust

Final Programme
## PROGRAMME SUMMARY

### TUESDAY 1 APRIL 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1300–1330</td>
<td>Registration open at Arena and Convention Centre Liverpool (New Consultants Forum Only)</td>
</tr>
<tr>
<td>1330–1600</td>
<td>New Consultants Forum</td>
</tr>
<tr>
<td>1615–2030</td>
<td>Registration open at Arena and Convention Centre Liverpool (BHIVA / BASHH Conference)</td>
</tr>
<tr>
<td>1650–1700</td>
<td>Welcome Addresses</td>
</tr>
<tr>
<td>1700–1800</td>
<td>Bristol-Myers Squibb Pharmaceuticals Satellite Symposium</td>
</tr>
<tr>
<td>1800–1930</td>
<td>BHIVA / BASHH Keynote Lecture</td>
</tr>
<tr>
<td>1930–2030</td>
<td>Welcome Reception: ACC Liverpool</td>
</tr>
<tr>
<td>2030–2215</td>
<td>ViiV Healthcare UK Evening Seminar</td>
</tr>
</tbody>
</table>

### WEDNESDAY 2 APRIL 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–1900</td>
<td>Registration and Exhibition open at Arena and Convention Centre Liverpool</td>
</tr>
<tr>
<td>0900–1000</td>
<td>BD Diagnostics Satellite Symposium</td>
</tr>
<tr>
<td>1000–1100</td>
<td>AbbVie Ltd Satellite Symposium</td>
</tr>
<tr>
<td>1100–1120</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1120–1220</td>
<td>Gilead Sciences Satellite Symposium</td>
</tr>
<tr>
<td>1220–1300</td>
<td>BHIVA / BASHH Review Session</td>
</tr>
<tr>
<td>1300–1500</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1310–1355</td>
<td>BHIVA / BASHH Lunchtime Workshops 1, 2 and 3</td>
</tr>
<tr>
<td>1355–1455</td>
<td>Sponsors' Lunchtime Workshops</td>
</tr>
<tr>
<td>1500–1630</td>
<td>Oral Research Presentations: Session 1</td>
</tr>
<tr>
<td>1630–1700</td>
<td>Afternoon tea</td>
</tr>
<tr>
<td>1700–1800</td>
<td>BHIVA / BASHH Plenary Session 1</td>
</tr>
<tr>
<td>1800–1900</td>
<td>MSD Ltd Satellite Symposium</td>
</tr>
<tr>
<td>1915–2000</td>
<td>Civic Reception: Matou Restaurant</td>
</tr>
</tbody>
</table>

### THURSDAY 3 APRIL 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0745–1830</td>
<td>Registration and Exhibition open at Arena and Convention Centre Liverpool</td>
</tr>
<tr>
<td>0800–0855</td>
<td>Launch of National Proforma to identify CSE in sexual health services</td>
</tr>
<tr>
<td>0900–1000</td>
<td>ViiV Healthcare UK Satellite Symposium</td>
</tr>
<tr>
<td>1000–1110</td>
<td>BHIVA / BASHH Plenary Session 2</td>
</tr>
<tr>
<td>1110–1135</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1135–1200</td>
<td>Parallel Sessions: MRC Clinical Trials Unit / NATSAL Sessions</td>
</tr>
<tr>
<td>1200–1300</td>
<td>Parallel Sessions: Oral Research Presentations: Sessions 2 and 3</td>
</tr>
<tr>
<td>1300–1500</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1310–1355</td>
<td>BHIVA / BASHH Lunchtime Workshops 4, 5 and 6</td>
</tr>
<tr>
<td>1355–1455</td>
<td>Sponsors' Lunchtime Workshops</td>
</tr>
<tr>
<td>1500–1630</td>
<td>Parallel Sessions: Oral Research Presentations: Sessions 4 and 5</td>
</tr>
<tr>
<td>1630–1700</td>
<td>Afternoon tea</td>
</tr>
<tr>
<td>1700–1720</td>
<td>BHIVA / BASHH Audit Session</td>
</tr>
<tr>
<td>1720–1820</td>
<td>BHIVA / BASHH Plenary Session 3</td>
</tr>
<tr>
<td>2000–0030</td>
<td>Gala Dinner: St George’s Hall</td>
</tr>
</tbody>
</table>

### FRIDAY 4 APRIL 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0800–1430</td>
<td>Registration and Exhibition open at Arena and Convention Centre Liverpool</td>
</tr>
<tr>
<td>0900–1000</td>
<td>Bristol-Myers Squibb Pharmaceuticals Satellite Symposium</td>
</tr>
<tr>
<td>1000–1030</td>
<td>BHIVA / BASHH Invited Lecture</td>
</tr>
<tr>
<td>1030–1100</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>1100–1200</td>
<td>Oral Research Presentations: Session 6</td>
</tr>
<tr>
<td>1200–1230</td>
<td>Oral Research Poster Presentations</td>
</tr>
<tr>
<td>1230–1430</td>
<td>Lunch, Workshops and Poster Presentations</td>
</tr>
<tr>
<td>1240–1325</td>
<td>BHIVA / BASHH Lunchtime Workshops 7, 8 and 9</td>
</tr>
<tr>
<td>1325–1425</td>
<td>Sponsors’ Lunchtime Workshops</td>
</tr>
<tr>
<td>1430–1445</td>
<td>BHIVA / BASHH Prizes and Awards Ceremony</td>
</tr>
<tr>
<td>1445–1535</td>
<td>BHIVA / BASHH Plenary Session 4</td>
</tr>
<tr>
<td>1535–1615</td>
<td>BHIVA / BASHH Plenary Session 5</td>
</tr>
<tr>
<td>1615</td>
<td>Close</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>1300</td>
<td>Registration open (BHIVA / BASHH New Consultants Forum only)</td>
</tr>
<tr>
<td>1330–1600</td>
<td>BHIVA / BASHH New Consultants Forum Room 11C, Upper Level (please see page 27 for further details)</td>
</tr>
<tr>
<td>1330–1340</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Mas Chaponda</td>
</tr>
<tr>
<td></td>
<td>Royal Liverpool University Hospital</td>
</tr>
<tr>
<td></td>
<td>Dr Emma Fox</td>
</tr>
<tr>
<td></td>
<td>Kent and Canterbury Hospitals NHS Trust</td>
</tr>
<tr>
<td>1340–1415</td>
<td>Getting published and improving your publication potential</td>
</tr>
<tr>
<td></td>
<td>Dr John White</td>
</tr>
<tr>
<td></td>
<td>Guy’s &amp; St Thomas’ NHS Foundation Trust, London</td>
</tr>
<tr>
<td>1415–1450</td>
<td>Making the most of opportunities to help career progression</td>
</tr>
<tr>
<td></td>
<td>Professor Jane Anderson</td>
</tr>
<tr>
<td></td>
<td>Homerton University Hospital, London</td>
</tr>
<tr>
<td>1450–1525</td>
<td>BASHH / BHIVA Mentoring Scheme</td>
</tr>
<tr>
<td></td>
<td>Dr Carol Emerson</td>
</tr>
<tr>
<td></td>
<td>The Royal Hospitals, Belfast</td>
</tr>
<tr>
<td>1525–1600</td>
<td>Setting up a new service</td>
</tr>
<tr>
<td></td>
<td>Dr Michael Rayment</td>
</tr>
<tr>
<td></td>
<td>Homerton University Hospital, London</td>
</tr>
<tr>
<td>1600</td>
<td>Close</td>
</tr>
<tr>
<td>1615–2030</td>
<td>Registration and exhibition open at ACC Liverpool</td>
</tr>
<tr>
<td>1650–1700</td>
<td>Welcome Addresses</td>
</tr>
<tr>
<td></td>
<td>Dr David Asboe</td>
</tr>
<tr>
<td></td>
<td>Chair, British HIV Association (BHIVA)</td>
</tr>
<tr>
<td></td>
<td>Dr Jan Clarke</td>
</tr>
<tr>
<td></td>
<td>President, British Association for Sexual Health and HIV (BASHH)</td>
</tr>
<tr>
<td>1700–1800</td>
<td>Bristol-Myers Squibb Pharmaceuticals Satellite Symposium</td>
</tr>
<tr>
<td>1800–1900</td>
<td>Janssen Satellite Symposium</td>
</tr>
<tr>
<td>1900–1930</td>
<td>BHIVA / BASHH Keynote Lecture</td>
</tr>
<tr>
<td></td>
<td>Chair: Professor Sheena McCormack</td>
</tr>
<tr>
<td></td>
<td>MRC Clinical Trials Unit at UCL, London</td>
</tr>
<tr>
<td></td>
<td>21st century prevention: vaccines for sexually transmitted infections, hepatitis and HIV</td>
</tr>
<tr>
<td></td>
<td>Professor Jonathan Weber</td>
</tr>
<tr>
<td></td>
<td>Imperial College London</td>
</tr>
<tr>
<td>1930–2030</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td></td>
<td>Hall 1A, Arena and Convention Centre Liverpool (please see page 30 for further details)</td>
</tr>
<tr>
<td></td>
<td>Chair: Dr Mark Lawton</td>
</tr>
<tr>
<td></td>
<td>Royal Liverpool University Hospital</td>
</tr>
<tr>
<td></td>
<td>Dr Alastair Miller</td>
</tr>
<tr>
<td></td>
<td>British HIV Association (BHIVA) Conference Subcommittee Chair</td>
</tr>
<tr>
<td></td>
<td>Dr Daniel Richardson</td>
</tr>
<tr>
<td></td>
<td>British Association for Sexual Health and HIV (BASHH) Conferences and Communications Secretary</td>
</tr>
<tr>
<td></td>
<td>Drinks and canapés to be served in Hall 2, Lower Level, following speeches</td>
</tr>
<tr>
<td>2030–2215</td>
<td>ViiV Healthcare UK Evening Seminar</td>
</tr>
<tr>
<td></td>
<td>Hall 2N, Lower Level</td>
</tr>
<tr>
<td></td>
<td>A light buffet supper will be provided. (please see page 20 for further details)</td>
</tr>
</tbody>
</table>
WEDNESDAY 2 APRIL 2014

0800–1900  Registration and exhibition open at ACC Liverpool

All sessions will be held in Hall 1A unless otherwise stated

0900–1000  BD Diagnostics Satellite Symposium (please see page 21 for further details)

1000–1100  AbbVie Ltd Satellite Symposium (please see page 21 for further details)

1100–1120  Morning Coffee

1120–1220  Gilead Sciences Satellite Symposium (please see page 21 for further details)

1220–1300  BHIVA / BASHH Review Session

Chairs: Professor Jonathan Ross
University Hospitals Birmingham NHS Trust
Dr Melinda Tenant-Flowers
King’s College Hospital NHS Foundation Trust, London

Translating recent research into clinical practice
Dr John White
Guy’s & St Thomas’ NHS Foundation Trust, London
Dr Laura Waters
University College London Medical School

1300–1500  Lunch, Workshops and Poster Presentations

1310–1355  BHIVA / BASHH Lunchtime Workshop 1 Hall 1A, Upper Level (please see page 27 for further details)

Clinico-pathological SpR Case Presentations
Chair: Professor Sebastian Lucas
St Thomas’ Hospital, London

An unusual cause of cystitis in an HIV-positive patient
Dr Jemy Thomas
Countess of Chester Hospital

Co-existing pathologies and anaemia in an HIV-infected returning traveller
Dr Dimitra Peppa
Mortimer Market Centre, London

The Clone Wars
Dr Jake Bayley
King’s College Hospital, London

1310–1355  BHIVA / BASHH Lunchtime Workshop 2 Room 4A, Upper Level
Lunch packs will be provided (See page 27 for further details)
Chair: Dr Mas Chaponda
Royal Liverpool University Hospital

Simplifying Antiretroviral Therapy (ART)
Dr Alastair Miller
Royal Liverpool University Hospital

1310–1355  BHIVA / BASHH Lunchtime Skills Workshop 3 Room 11C, Upper Level
Lunch packs will be provided (See page 27 for further details)
Chair: Ms Sheila Morris
Western General Hospital, Edinburgh

HIV in later life: impact on mental health
Dr Ravneet Batra
Western General Hospital, Edinburgh
Dr Dana Rosenfeld
Keele University, Newcastle-under-Lyme
PROGRAMME

WEDNESDAY 2 APRIL 2014

1355–1455  Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop Room 11B, Upper Level (please see page 22 for further details)

1355–1455  Janssen Lunchtime Workshop Room 4B, Upper Level (please see page 22 for further details)

1355–1455  ViiV Healthcare Lunchtime Workshop Room 11A, Upper Level (please see page 22 for further details)

1500–1630 Oral Research Presentations: Session 1

Antiretroviral therapy and its complications

Chair: Professor Clifford Leen
Western General Hospital, Edinburgh

Dr Janet Wilson
Leeds Teaching Hospitals NHS Trust

1500–1510 Abstract O1
The Protease Inhibitor Versus Ongoing Triple-therapy (PIVOT) trial
Professor Nicholas Paton, MRC Clinical Trials Unit at UCL, London

1510–1520 Abstract O2
Attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: Week 24 analysis
Dr Max Lataillade, Bristol-Myers Squibb Pharmaceuticals

1520–1530 Abstract O3
How would health care professionals (HCP) who care for HIV patients treat themselves or a family member if they were HIV+?
Dr Laura Waters, Mortimer Market Centre, London

1530–1540 Abstract O4
Multicenter open-label study of switching from Atripla to Eviplera for CNS toxicity
Miss Jane Rowlands, Chelsea and Westminster Hospital, London

1540–1550 Abstract O5
Variation in mode of delivery for HIV-positive women in UK & Irish hospitals, 2008–2013
Miss Helen Peters, University College London Institute of Child Health

1550–1600 Abstract O6
The clinical utility of therapeutic drug level monitoring of Atazanavir and Darunavir in pregnancy
Dr Margaret Kingston, Manchester Royal Infirmary

1600–1610 Abstract O7
Recommendation for the off-licence use of maraviroc in children with perinatally acquired HIV-1 infection by a regional paediatric virtual clinic
Dr Caroline Foster, Imperial College Healthcare NHS Trust, London

1610–1620 Abstract O8
Temporal trends in cART initiation amongst HIV seroconverters in the UK
Mrs Victoria Parsons, University College London

1620–1630 Abstract O9
HIV and health-related quality-of-life in the UK – where are we now?
Dr Alec Miners, London School of Hygiene and Tropical Medicine

1630–1700  Afternoon Tea
# Programme

## Wednesday 2 April 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1700–1800</td>
<td><strong>BHIVA / BASHH Plenary Session 1: Clinical topics</strong>&lt;br&gt;<strong>Chairs:</strong> Dr Duncan Churchill&lt;br&gt;</td>
</tr>
<tr>
<td></td>
<td><em>Brighton and Sussex University Hospitals NHS Trust</em></td>
</tr>
<tr>
<td></td>
<td>Dr Fiona Lyons&lt;br&gt;<em>St James’s Hospital, Dublin, Ireland</em></td>
</tr>
<tr>
<td></td>
<td><strong>Cardiovascular disease: risk assessment, risk reduction</strong>&lt;br&gt;Dr James Coutts&lt;br&gt;<em>St Thomas’ Hospital, London</em>&lt;br&gt;<strong>Management of sustained low level viraemia</strong>&lt;br&gt;Professor Anna Maria Geretti&lt;br&gt;<em>Institute of Infection &amp; Global Health, University of Liverpool</em>&lt;br&gt;<strong>Enteric infections in men who have sex with men</strong>&lt;br&gt;Professor Brian Gazzard&lt;br&gt;<em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td>1800–1900</td>
<td><strong>MSD Ltd Satellite Symposium</strong> <em>(please see page 22 for further details)</em></td>
</tr>
<tr>
<td>1915–2030</td>
<td><strong>Civic Reception</strong> <em>(please see page 30 for further details)</em>&lt;br&gt;<strong>Chairs:</strong> Dr Alastair Miller&lt;br&gt;<em>British HIV Association (BHIVA) Conferences Subcommittee Chair</em>&lt;br&gt;Dr Daniel Richardson&lt;br&gt;<em>British Association for Sexual Health and HIV (BASHH) Conferences Secretary</em>&lt;br&gt;Councillor Gary Millar&lt;br&gt;<em>The Right Worshipful, The Lord Mayor of the City of Liverpool</em>&lt;br&gt;Dr David Asboe&lt;br&gt;<em>Chair, British HIV Association (BHIVA)</em>&lt;br&gt;Dr Jan Clarke&lt;br&gt;<em>President, British Association for Sexual Health and HIV (BASHH)</em></td>
</tr>
</tbody>
</table>
### Thursday 3 April 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0745-1820</td>
<td>Registration desk and exhibition open at ACC Liverpool</td>
</tr>
<tr>
<td></td>
<td>All sessions will be held in Hall 1A unless otherwise stated</td>
</tr>
<tr>
<td>0800-0855</td>
<td>Launch of National Proforma to identify child sexual exploitation (CSE) in sexual health services Room 4A, Upper Level <em>(please see page 23 for further details)</em></td>
</tr>
<tr>
<td>0900-1000</td>
<td>ViiV Healthcare Satellite Symposium <em>(please see page 23 for further details)</em></td>
</tr>
<tr>
<td>1000-1110</td>
<td>BHIVA / BASHH Plenary Session 2: Clinical and community practice</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Mr Garry Brough</td>
</tr>
<tr>
<td></td>
<td><strong>UK Community Advisory Board (UK-CAB)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Dr Margaret Kingston</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Central Manchester University Hospitals NHS Foundation Trust</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Strategies for retaining people living with HIV in care</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Vanessa Apea</td>
</tr>
<tr>
<td></td>
<td><em>Barts Health NHS Trust, London</em></td>
</tr>
<tr>
<td></td>
<td><strong>Ms Eileen Nixon</strong></td>
</tr>
<tr>
<td></td>
<td><em>Brighton and Sussex University Hospitals NHS Trust</em></td>
</tr>
<tr>
<td></td>
<td><strong>HIV testing: new technologies and new strategies for those at higher risk</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Alan McOwan</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td><strong>Partner notification for HIV: maximising positive outcomes</strong></td>
</tr>
<tr>
<td></td>
<td>Dr Ann Sullivan</td>
</tr>
<tr>
<td></td>
<td><em>Chelsea and Westminster Hospital, London</em></td>
</tr>
<tr>
<td>1110-1135</td>
<td>Morning Coffee</td>
</tr>
<tr>
<td>1135-1300</td>
<td><strong>Parallel Sessions</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Note:</strong> The MRC and NATSAL sessions and Oral Research Presentation Sessions 2 and 3 will run in parallel. Please check the location of these Sessions carefully</td>
</tr>
<tr>
<td>1135-1200</td>
<td>MRC Clinical Trials Unit Session Room 11, Upper Level</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Professor Martin Fisher</td>
</tr>
<tr>
<td></td>
<td><em>Brighton and Sussex University Hospitals NHS Trust</em></td>
</tr>
<tr>
<td></td>
<td><strong>Protease inhibitors: what’s the best companion?</strong></td>
</tr>
<tr>
<td></td>
<td>Professor Nick Paton</td>
</tr>
<tr>
<td></td>
<td><em>MRC Clinical Trials Unit at UCL, London</em></td>
</tr>
<tr>
<td></td>
<td>Professor Abdel Babiker</td>
</tr>
<tr>
<td></td>
<td><em>MRC Clinical Trials Unit at UCL, London</em></td>
</tr>
<tr>
<td>1135-1200</td>
<td>National Survey of Sexual Attitudes and Lifestyle (NATSAL) Session Hall 1A, Upper Level</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Dr John White</td>
</tr>
<tr>
<td></td>
<td><em>St Thomas’ Hospital, London</em></td>
</tr>
<tr>
<td></td>
<td>Professor Anne Johnson</td>
</tr>
<tr>
<td></td>
<td><em>UCL Institute of Epidemiology and Health Care, London</em></td>
</tr>
</tbody>
</table>
THURSDAY 3 APRIL 2014

1200–1300  Oral Research Presentations: Session 2 Room 11, Upper Level
Basic science and immunology

Chairs: Professor Mark Bower  
     Chelsea and Westminster Hospital, London
Dr Elizabeth Foley  
     Royal South Hants Hospital

1200–1210 Abstract O10
Evaluation of circulating gut-homing T cells as a marker of HIV-1 progression and immune reconstitution
Dr Lucy Dorrell, University of Oxford

1210–1220 Abstract O11
Beneficial effect of NNRTI over boosted PI first line cART on CD4 T-cell restoration in older HIV-1+ patients
Dr Anna Herasimtschuk, Imperial College London

1220–1230 Abstract O12
Protection versus pathology in aviremic and high viral load HIV-2 infection – the pivotal role of immune activation and T-cell kinetics
Professor Derek Macallan, St George’s, University of London

1230–1240 Abstract O13
IP-10 levels in HIV/HCV co-infection decrease with the initiation of successful antiretroviral (ART) therapy: Implications for earlier ART in co-infected patients
Dr Kate Childs, King’s College Hospital NHS Foundation Trust, London

1240–1250 Abstract O14
The effect of HCV infection duration on HIV disease progression
Mr Jamie Inshaw, University College London

1250–1300 Abstract O15
Immunological efficacy of a prime-boost vaccine strategy combining the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) versus PPV 23 alone in HIV-infected adults
Dr Corinna Sadlier, St James’s Hospital, Dublin, Ireland

1200–1300  Oral Research Presentations: Session 3 Hall 1A, Upper Level
Service delivery

Chairs: Professor Christopher Fairley  
     The University of Melbourne, Australia
Dr Adrian Palfreeman  
     Leicester Royal Infirmary

1200–1210 Abstract O16
Less is more: The impact of a new senior model on clinic throughput and its ability to support staff to reach their full potential
Dr Anatole Menon-Johansson, Guy’s & St Thomas’ NHS Foundation Trust, London

1210–1220 Abstract O17
ePN: electronic partner notification is an effective, efficient method to deliver partner notification and capture verified outcomes
Dr Ann Sullivan, Chelsea and Westminster Hospital, London

1220–1230 Abstract O18
Active recall for HIV/STI testing: a systematic review
Dr Monica Desai, Public Health England
THURSDAY 3 APRIL 2014

1230–1240 Abstract O19
Patients’ referral pathway in the first year of HIV care
Dr Zheng Yin, Public Health England

1240–1250 Abstract O20
Trends in HIV testing outside of traditional services
Ms Sarah Collins, Public Health England

1250–1300 Abstract O21
Home HIV sampling linked to national HIV testing campaigns: a novel approach to improve HIV diagnosis
Dr Michael Brady, Terrence Higgins Trust

1300–1500 Lunch, Workshops and Poster Presentations

1310–1355 BHIVA / BASHH Lunchtime Workshop 4 Hall 1A, Upper Level (please see page 27 for further details)
Legal responses to HIV & other STIs: professional obligations, medical ethics and public health
Dr Mark Lawton
Royal Liverpool University Hospital
Professor Matthew Weait
Birkbeck, University of London

1310–1355 BHIVA / BASHH Lunchtime Workshop 5 Room 11, Upper Level
Lunch packs will be provided (See page 27 for further details)
Pregnancy, breastfeeding and HIV: Experience and case presentations
Chair: Dr Annemiek de Ruiter
St Thomas’ Hospital, London
Panel
Dr Fiona Lyons
St James’s Hospital, Dublin, Ireland
Dr Andrew Riordan
Alder Hey Children’s NHS Foundation Trust, Liverpool

Third trimester conundrum
Dr Subathira Dakshina
Barts Health NHS Trust
The challenges of adherence during pregnancy
Dr Olivia Drew
Solent NHS Trust
Clinical dilemmas in supporting women living with HIV to breastfeed
Ms Emma Macfarlane
Barking, Havering and Redbridge University Hospitals NHS Trust

1310–1355 BHIVA / BASHH Lunchtime Skills Workshop 6 Room 13, Upper Level
Lunch packs will be provided (See page 27 for further details)
Chair: Dr Michael Brady
King’s College Hospital NHS Foundation Trust, London
Preventing sexually transmitted infection re-infection
Dr Claudia Escourt
Barts and the London School of Medicine and Dentistry

1355–1455 Cepheid Lunchtime Workshop Room 4B, Upper Level (please see page 24 for further details)

1355–1455 Janssen Lunchtime Workshop Room 4A, Upper Level (please see page 24 for further details)
THURSDAY 3 APRIL 2014

1500–1630 Parallel Sessions
Note: Oral Research Presentation Sessions 4 and 5 will run in parallel. Please check the location of these Sessions carefully

1500–1630 Oral Research Presentations: Session 4 Room 11, Upper Level
Complications and co-morbidities
Chairs: Dr Daniel Richardson
Brighton and Sussex University Hospitals NHS Trust
Professor Caroline Sabin
University College London

1500–1510 Abstract O22
A hepatitis C virus core antigen assay is a cost-effective, sensitive and specific test in the detection of acute hepatitis C infection in HIV-infected subjects
Mr Robert Carney, Royal Free London NHS Foundation Trust

1510–1520 Abstract O23
Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-positive men with acute HCV
Dr Daniel Bradshaw, Kirby Institute, University of New South Wales Sydney, Australia

1520–1530 Abstract O24
Second malignancies in patients with Kaposi’s sarcoma (KS): Does systemic chemotherapy contribute to the risk?
Miss Maggie Smith, Chelsea and Westminster Hospital, London

1530–1540 Abstract O25
End-stage kidney disease and kidney transplantation in HIV-positive patients in the UK Collaborative HIV Cohort (CHIC) Study
Ms Sophie Jose, University College London

1540–1550 Abstract O26
Management of cardiovascular risk in HIV-positive individuals in Europe
Dr Maryam Shahmanesh, University College London

1550–1600 Abstract O27
Disease burden due non-chronic viral hepatitis-related liver disease in HIV-positive individuals: preliminary results from a longitudinal cohort study
Dr Natalie Shur, The Royal Sussex County Hospital, Brighton

1600–1610 Abstract O28
Attitude of HIV patients towards organ transplant between HIV patients
Dr Huda Taha, Coventry and Warwickshire Partnership Trust

1610–1620 Abstract O29
Facilitating self-care in HIV with digital patient-controlled health records
Dr Zoe Warwick, Plymouth Hospitals NHS Trust

1620–1630 Abstract O30
Validation of the rationalisation of routine blood tests and visits for HIV-1-infected individuals
Dr Alastair Teague, Guy’s & St Thomas’ NHS Foundation Trust, London

1500–1630 Oral Research Presentations: Session 5 Hall 1A, Upper Level
Sexually transmitted infections
Chairs: Dr Gillian Dean
Brighton and Sussex University Hospitals NHS Trust
Dr Alastair Miller
Royal Liverpool University Hospital
THURSDAY 3 APRIL 2014

1500–1510 Abstract O31
The epidemiology of Mycoplasma genitalium in the British population: Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)
Dr Pam Sonnenberg, University College London

1510–1520 Abstract O32
The prevalence of Mycoplasma genitalium among male GUM attendees using an in-house PCR on BD Max platform
Ms Rebecca Slack, Sheffield Teaching Hospitals

1520–1530 Abstract O33
Human papillomavirus infection and cervical cancer prevention in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)
Dr Clare Tanton, University College London

1530–1540 Abstract O34
Feasibility and acceptability of a quadrivalent human papillomavirus vaccination programme (HPV4) for young men who have sex with men (MSM) within a comprehensive sexually transmitted infection (STI) testing and sexual health engagement strategy: Results from the first year
Dr John McSorley, North West London Hospitals NHS Trust

1540–1550 Abstract O35
High-risk drug practices associated with Shigella flexneri serotype 3a infections amongst men who have sex with men (MSM) in England
Ms Victoria Gilbart, Public Health England

1550–1600 Abstract O36
Gastroenterology out-patient clinic: rectal pain and discharge associated with a history of receptive anal sex in women
Dr Sarah Allstaff, NHS Tayside, Scotland

1600–1610 Abstract O37
Highly diverse genotypes of rectal Chlamydia trachomatis, using multi-locus VNTR analysis (MLVA)-ompA sequencing, among men who have sex with men (MSM) attending a GUM clinic
Dr Judith Zhou, Brighton and Sussex University Hospitals NHS Trust

1610–1620 Abstract O38
Performance of ceftriaxone 500mg-containing regimens for treatment of genital and extra-genital gonorrhoea
Dr Selena Singh, Guy's & St Thomas' NHS Foundation Trust, London

1620–1630 Abstract O39
Detection of HIV-1 viral load in the rectum
Dr Julie Fox, Guy's & St Thomas' NHS Foundation Trust, London

1630–1700 Afternoon Tea

1700–1720 BHIVA / BASHH Audit Session
Chairs: Dr Andrew Freedman
Cardiff University School of Medicine
Dr Hugo McClean
City Health Care Partnership Hull

BASHH national audit on the management of anogenital herpes
Dr Anatole Menon-Johansson
Guy's & St Thomas' NHS Foundation Trust, London
THURSDAY 3 APRIL 2014

1720–1820  BHIVA / BASHH Plenary Session 3: The virtual clinic

Chairs: Professor Brian Angus
University of Oxford
Dr David Phillips
Croydon University Hospital

Managing men with *M. genitalium* urethritis
Professor Jonathan Ross
University Hospitals Birmingham NHS Trust

Investigating pyrexia of unknown origin
Dr Andy Ustianowski
North Manchester General Hospital

Safeguarding and sexual health in HIV
Ms Linda Furness
Cardiff Royal Infirmary

2000–0030  Gala Dinner *(please see page 30 for further details)*
St George’s Hall
FRIDAY 4 APRIL 2014

0800–1430 Registration desk and exhibition open at ACC Liverpool

All sessions will be held in Hall 1A unless otherwise stated

0900–1000 Bristol-Myers Squibb Pharmaceuticals Satellite Symposium (please see page 25 for further details)

1000–1030 BHIVA / BASHH Invited Lecture
Chair: Dr Leena Sathia
Royal Free Hampstead NHS Trust, London

Syphilis: immunology and HIV
Professor Christina Marra
University of Washington School of Medicine, USA

1030–1100 Morning Coffee

1100–1200 Oral Research Presentations: Session 6
Lifestyle and HIV Transmission

Chairs: Dr Lucy Dorrell
University of Oxford
Dr Alan McOwan
Chelsea and Westminster Hospital, London

1100–1110 Abstract O40
Sex, drugs and STIs
Dr Nadia Ekong, Leeds Centre for Sexual Health

1110–1120 Abstract O41
High levels of recreational drug use (RDU) in HIV clinics - concerns for onward HIV transmission and adherence with treatment
Dr Selena Singh, Guy's & St Thomas' NHS Foundation Trust, London

1120–1130 Abstract O42
Psychological interventions to reduce sexual risk-taking
Dr Dorota Jagielska-Hall, Homerton University Hospital, London

1130–1140 Abstract O43
Who accesses PrEP? An analysis of baseline data in the PROUD pilot
Dr Monica Desai, Public Health England

1140–1150 Abstract O44
Understanding the acceptability of pre-exposure prophylaxis (PrEP) for HIV prevention amongst gay and bisexual men in Scotland: a mixed methods study
Dr Jamie Frankis, Glasgow Caledonian University

1150–1200 Abstract O45
Acute Hepatitis C in the PROUD pilot study
Dr Juan Tiraboschi, Guy's & St Thomas' NHS Foundation Trust, London

1200–1230 Oral Research Poster Presentations

Chairs: Dr Carol Emerson
The Royal Hospitals, Belfast
Dr Danielle Mercey
Central & North West London NHS Foundation Trust

1230–1430 Lunch, Workshops and Poster Presentations
## PROGRAMME

### FRIDAY 4 APRIL 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1240–1325 | BHIVA / BASHH Lunchtime Workshop 7 Hall 1A, Upper Level *(please see page 27 for further details)*  
**Chair:** Dr Simon Barton  
*Chelsea and Westminster Hospital, London*  
**BHIVA / BASHH Commissioning workshop: members’ report on challenges and opportunities**  
Dr David Asboe  
*Chelsea and Westminster Hospital, London*  
Dr Janet Wilson  
*Leeds Teaching Hospitals NHS Trust*  
Ms Kate Folkard  
*Public Health England* |
| 1240–1325 | BHIVA / BASHH Lunchtime Workshop 8 Room 11B, Upper Level  
*Lunch packs will be provided (See page 27 for further details)*  
**Polypharmacy and shared care issues: bridging primary and secondary care systems**  
**Chair:** Mr Ben Cromorty  
*North Yorkshire AIDS Action*  
Professor Saye Khoo  
*University of Liverpool* |
| 1240–1325 | BHIVA / BASHH Lunchtime Skills Workshop 9 Room 11C, Upper Level  
*Lunch packs will be provided (See page 27 for further details)*  
**Benefits of international exchange scholarships: looking back, looking ahead**  
**Chair:** Dr Sanjay Bhagani  
*Royal Free Hospital, London*  
Ms Dola Awoyemi  
*Kingston Hospital, London*  
Dr Analia Urueña  
*Helios Salud, Buenos Aires, Argentina*  
Dr Subathira Dakshina  
*Barts Health NHS Trust, London*  
Dr Alexandra Clarissa Teleka  
*Blantyre District Health Office, Malawi*  
**Panel:**  
Dr Ranjababu Kulasegaram  
*St Thomas' Hospital, London* |
| 1325–1425 | Gilead Sciences Lunchtime Workshop Room 4A, Upper Level *(please see page 25 for further details)* |
| 1325–1425 | ViiV Healthcare Lunchtime Workshop Room 4B, Upper Level *(please see page 25 for further details)* |
FRIDAY 4 APRIL 2014

1325–1425 BHIVA / BASHH Lunchtime Workshop 10 Room 11A, Upper Level (please see page 27 for further details)
Managing the complexities of pharmacology in HIV / hepatitis C co-infected patients
Professor David Back
University of Liverpool
Professor Massimo Puoti
Niguarda Ca Granda Hospital, Milan, Italy
BHIVA is grateful for an educational grant in support of this workshop from Boehringer Ingelheim
Please see page 27 for further details

1430–1445 BHIVA / BASHH Prizes and Awards Ceremony

1445–1535 BHIVA / BASHH Plenary Session 4
Chairs: Dr Paddy Horner
University of Bristol
Dr Ranjababu Kulasegaram
St Thomas’ Hospital, London
HPV vaccination in men who have sex with men
Professor Christopher Fairley
The University of Melbourne, Australia
Hepatitis C: when to treat and when to wait
Professor Massimo Puoti
Niguarda Ca Granda Hospital, Milan, Italy

1535–1615 BHIVA / BASHH Plenary Session 5
Chairs: Dr David Asboe
Chelsea and Westminster Hospital, London
Dr Mette Rodgers
Croydon University Hospital
Chem-sex: Why is it problematic and what can we do about it?
Dr Ann Sullivan
Chelsea and Westminster Hospital, London
Dr Adam Winstock
King’s College Hospital, London

1615 Close

Dr David Asboe
Chair, British HIV Association (BHIVA)

Dr Jan Clarke
President, British Association for Sexual Health and HIV (BASHH)
LIFE’S A JOURNEY.

Twice daily. For weight-based dosing, of patients ≥/ ≤0.5 to <0.8 m², 2 tablets twice daily. BSA ≥0.8 to ≥0.9 to <1.4 m² (>25 to 35 kg), 3 tablets twice daily. BSA ≥1.4 m² (>35 kg) twice daily. Children under 2 years, pregnant women, patients with hepatic or renal insufficiency, children under 40 kg or with a BSA between 0.5 and 1.4 m² use 2 tablets twice daily. BSA ≥0.9 to <1.4 m² (>25 to 35 kg), 3 tablets twice daily. BSA ≥1.4 m² (>35 kg) twice daily. Co-administration with efavirenz or nevirapine. BSA ≤5.0 to ≥0.8 m². 2 tablets twice daily BSA ≤0.8 to <1.2, 3 tablets twice daily. BSA ≤1.2 to ≤1.4, 4 tablets twice daily, BSA >1.4 to 5 tablets twice daily. For convenience 200/50 mg and 100/25 mg tablets may be combined to achieve the recommended dose. Once daily dosing has not been evaluated in paediatrics.

Contraindications: Lopinavir and ritonavir are contraindicated in patients with known hypersensitivity to any component of the formulation. Severe hepatic insufficiency. Do not co-administer with medicinal products highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events, including astemizole, terfenadine, pimozide, quetiapine, ergot alkaloids, cisapride, astemizole, terfenadine, pimozide, quetiapine, ergot alkaloids, cisapride, which elevated plasma concentrations are associated with serious and/or life-threatening events. Co-administration with cyclosporin, sirolimus and tacrolimus requires caution and clinical monitoring. Dexamethasone may decrease lopinavir concentrations. Cyclosporin, sirolimus and tacrolimus concentrations may be increased. Caution in co-administration with maraviroc (see SmPC). Concomitant use with efavirenz, nevirapine, amprenavir, carbamazepine, phenobarbital and valproate. Lamotrigine should be used with caution in patients on concomitant therapy with lopinavir/ritonavir if prolonged QT interval is present. Lopinavir/ritonavir increases in ARV-naïve patients. Kaletra is contraindicated in patients with cirrhosis who are likely to increase the risk of a lesser sustainability of the virologic suppression and higher risk of virologic failure compared to the recommended standard twice daily dosing. See SmPC for full details. Children under 2 years of age: Oral Solution: 200/50 mg twice daily with food. Maximum dose 400/100 mg twice daily. For weight-based dosing, of patients ≥15 to 40 kg, 100 mg/kg twice daily as a single dose. Should not be administered once daily in combination with ritonavir or other inhibitors of CYP3A and are likely to increase plasma concentrations of products primarily metabolized by CYP3A. Avoid concomitant administration with coenzyme Q10, particularly in patients with renal or hepatic impairment. Combination with other antiretroviral medicinal products for the treatment of HIV infection in adults, adolescents and children over 2 years.

Dosage and Administration: Adults & Adolescents: Standard recommended dosage is 400/100 mg (two 200/50 mg tablets or four 100/25 mg tablets twice daily with or without food. May be administered as 800/200 mg (four 200/50 mg tablets) once daily with or without food, where appropriate. Once daily dosing should be limited to those adult patients having <3 protease inhibitor (PI) associated mutations in line with clinical trial results and should take into account the risk of a lesser sustainability of the virologic suppression and higher risk of diastolic compared to the recommended standard twice daily dosing. See SmPC for full details. Children under 2 years of age: Oral Solution: 200/50 mg twice daily with food. Maximum dose 400/100 mg twice daily. For weight-based dosing, of patients ≥15 to 40 kg, 100 mg/kg twice daily as a single dose. Should not be administered once daily in combination with ritonavir or other inhibitors of CYP3A and are likely to increase plasma concentrations of products primarily metabolized by CYP3A. Avoid concomitant administration with coenzyme Q10, particularly in patients with renal or hepatic impairment. Combination with other antiretroviral medicinal products for the treatment of HIV infection in adults, adolescents and children over 2 years.

DOSAGE AND ADMINISTRATION: Adults & Adolescents: Oral Solution 5 ml (200/50 mg) twice daily with food. Film-coated tablets. Standard recommended dosage is 400/100 mg (two 200/50 mg tablets or four 100/25 mg tablets twice daily with or without food. May be administered as 800/200 mg (four 200/50 mg tablets) once daily with or without food, where appropriate. Once daily dosing should be limited to those adult patients having <3 protease inhibitor (PI) associated mutations in line with clinical trial results and should take into account the risk of a lesser sustainability of the virologic suppression and higher risk of diastolic compared to the recommended standard twice daily dosing. See SmPC for full details. Children under 2 years of age: Oral Solution: 200/50 mg twice daily with food. Maximum dose 400/100 mg twice daily. For weight-based dosing, of patients ≥15 to 40 kg, 100 mg/kg twice daily as a single dose. Should not be administered once daily in combination with ritonavir or other inhibitors of CYP3A and are likely to increase plasma concentrations of products primarily metabolized by CYP3A. Avoid concomitant administration with coenzyme Q10, particularly in patients with renal or hepatic impairment. Combination with other antiretroviral medicinal products for the treatment of HIV infection in adults, adolescents and children over 2 years.

DOSAGE AND ADMINISTRATION: Adults & Adolescents: Oral Solution 5 ml (200/50 mg) twice daily with food. Film-coated tablets. Standard recommended dosage is 400/100 mg (two 200/50 mg tablets or four 100/25 mg tablets twice daily with or without food. May be administered as 800/200 mg (four 200/50 mg tablets) once daily with or without food, where appropriate. Once daily dosing should be limited to those adult patients having <3 protease inhibitor (PI) associated mutations in line with clinical trial results and should take into account the risk of a lesser sustainability of the virologic suppression and higher risk of diastolic compared to the recommended standard twice daily dosing. See SmPC for full details. Children under 2 years of age: Oral Solution: 200/50 mg twice daily with food. Maximum dose 400/100 mg twice daily. For weight-based dosing, of patients ≥15 to 40 kg, 100 mg/kg twice daily as a single dose. Should not be administered once daily in combination with ritonavir or other inhibitors of CYP3A and are likely to increase plasma concentrations of products primarily metabolized by CYP3A. Avoid concomitant administration with coenzyme Q10, particularly in patients with renal or hepatic impairment. Combination with other antiretroviral medicinal products for the treatment of HIV infection in adults, adolescents and children over 2 years.

Protection tomorrow, starts today

The HIV-positive population in the UK is ageing, bringing a greater incidence of co-morbidities vs. HIV-negative patients.

Kaletra® has been proven to:

- Treat an ageing treatment-experienced population
- Deliver 7-year virological efficacy with CD4 increases in ARV-naive patients
- Demonstrate similar efficacy in women and men at 48 weeks

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AbbVie Ltd on 01628 749393.

References:
SATELLITE SYMPOSIA
SEMINARS AND WORKSHOPS

TUESDAY 1 APRIL 2014

All satellite symposia will be held in Hall 1A, Upper Level
Locations of workshops and evening seminars are listed below adjacent to the respective events

1700–1800  Bristol-Myers Squibb Pharmaceuticals Satellite Symposium
Partnering for HIV cure: The limits of cART
Chair: Professor Jonathan Weber
  Imperial College, London
A foundation for cure: bridging the gap with cART
Dr Mark Nelson
Chelsea and Westminster Hospital, London
Management of primary HIV infection: opportunities and challenges
Dr Sarah Fidler
Imperial College, London

1800–1900  Janssen Satellite Symposium
HIV 2020 vision: focusing on the future of HIV treatment
Welcome and introduction
Professor Jane Anderson
Homerton University Hospital, London
Changing the ARV treatment paradigm
Dr Mas Chaponda
Royal Liverpool Hospitals
Moving forward the agenda on HIV cure
Dr John Frater
University of Oxford
Future innovations in medical technology
Dr Bertalan Meskó
Medical Futurist

2030–2215  ViiV Healthcare UK Evening Seminar Hall 2N, Lower Level (adjacent to Exhibition Hall)
A light buffet supper will be provided. Entrance on a first-come, first-served basis.
Doors open 10 minutes prior to Seminar.
Let’s talk: What matters in HIV?
Chair: Mr Richard Phillips
  ViiV Healthcare UK
Professor Brian Gazzard
Chelsea and Westminster Hospital, London
Dr Anton Pozniak
Chelsea and Westminster Hospital, London
Dr Julie Fox
Guy’s and St Thomas’ NHS Foundation Trust, London
Dr Yusef Azad
National AIDS Trust
WEDNESDAY 2 APRIL 2014

All satellite symposia will be held in Hall 1A, Upper Level
Locations of workshops and evening seminars are listed below adjacent to the respective events

0900–1000

**BD Diagnostics Satellite Symposium**

*How to manage Mycoplasma genitalium as an STD*

Dr Harald Moi  
*University of Oslo, Norway*

*How important is nucleic acid contamination within a sexual health clinic?*

Professor Jonathan Ross  
*University Hospitals Birmingham NHS Foundation Trust*

1000–1100

**AbbVie Ltd Satellite Symposium**

*Positive ageing with HIV: a patient-centred approach*

Dr Tristan Barber  
*Mortimer Market Centre, London*

Dr Laura Waters  
*Mortimer Market Centre, London*

Mr Robert Fieldhouse  
*BASELINE*

Professor Brian Gazzard  
*Chelsea and Westminster Hospital, London*

1120–1220

**Gilead Sciences Satellite Symposium**

*HIV I got news for you*

Chair: Dr Simon Barton  
*Chelsea and Westminster Hospital, London*

Dr Andrew Ustianowski  
*North Manchester General Hospital*

Dr Colm O’Mahony  
*Countess of Chester Hospital NHS Trust, Chester*

Prof Jane Anderson  
*Mortimer Market Centre, London*

Dr Anton Pozniak  
*Chelsea and Westminster Hospital, London*

Dr Karen Rogstad  
*Sheffield Teaching Hospitals NHS Foundation Trust*

Dr Mark Lawton  
*Royal Liverpool University Hospital*
WEDNESDAY 2 APRIL 2014

All satellite symposia will be held in Hall 1A, Upper Level
Locations of workshops and evening seminars are listed below adjacent to the respective events

1355–1455  Bristol-Myers Squibb Lunchtime Workshop  Room 11B, Upper Level
Ageing positively: Women with HIV, treatment now and in the future
Chair: Dr Mas Chaponda
Royal Liverpool University Hospital
Dr Fatima Ibrahim
St. Peter’s Health Centre, Leicester
Professor Fiona Mulcahy
St James’s Hospital, Dublin, Ireland

1355–1455  Janssen Lunchtime Workshop  Room 4B, Upper Level
Unlocking patient potential in HIV management
Chair: Mr Allan Anderson
Positively UK
Dr Mohammad Al-Ubaydli
Patients Know Best
Dr Michael Brady
King’s College Hospital, London
Mr Paul Decle
Patient Representative, Chelsea and Westminster Hospital

1355–1455  ViiV Healthcare Lunchtime Workshop  Room 11A, Upper Level
Resistance in the current era of HIV Management: clinical challenges
Chair: Professor Anna Maria Geretti
University of Liverpool
Dr Marta Boffito
Chelsea and Westminster Hospital, London
Dr Tomas Doyle
Royal Free Hospital, London

1800–1900  MSD Ltd Satellite Symposium
HIV: At a Crossroads?
Chair: Dr Andrew Ustianowski
North Manchester General Hospital
Dr Simon Barton
Chelsea and Westminster Hospital, London
Dr Tristan Barber
Homerton University Hospital, London
Dr Ed Wilkins
North Manchester General Hospital
THURSDAY 3 APRIL 2014

All satellite symposia will be held in Hall 1A, Upper Level
Locations of workshops and evening seminars are listed below adjacent to the respective events

0800–0855

**Spotting the signs: a national proforma for identifying risk of child sexual exploitation in sexual health services**

A Department of Health funded project delivered by British Association of Sexual Health & HIV (BASHH) and Brook Room 4A, Upper Level

A light breakfast of Danish pastries and refreshments will be provided.

**Chairs:** Dr Janet Wilson  
Immediate Past President, British Association for Sexual Health & HIV  
Mr Simon Blake  
Chief Executive, Brook

**Background and context of project**

Ms Andrea Duncan  
Department of Health

**Video Messages**

Jane Ellison MP  
Parliamentary Under Secretary of State for Public Health

Norman Baker MP  
Minister of State for Crime Prevention

**CSE in gangs and groups**

Ms Claire Manchester  
Metropolitan Police and London Multiagency Safeguarding Hub

**Methodology, results of focus groups, pilot results and final proforma**

Dr Karen Rogstad  
Chair of BASHH Advisory Board and Working Group

**Panel Discussion**

Ms Sarah Doran  
Greater Manchester Sexual Health Network

Mr Duy Hoang  
Brook P+ Volunteer

Ms Andrea Duncan  
Department of Health

Dr Dawn Wilkinson  
Chair, BASHH Adolescent Special Interest Group

Dr Karen Rogstad  
Chair, BASHH Advisory Board and Working Group

0900–1000

**ViiV Healthcare Satellite Symposium**

**HIV Treatment So Far So Good ... Can We Do Better?**

**Chair:** Dr Mark Nelson  
Chelsea and Westminster Hospital, London

Dr Laura Waters  
Mortimer Market Centre, London

Dr Nicola Mackie  
St Mary’s Hospital, London
THURSDAY 3 APRIL 2014

All satellite symposia will be held in Hall 1A, Upper Level
Locations of workshops and evening seminars are listed below adjacent to the respective events

1355–1455  Cepheid Lunchtime Workshop Room 4B, Upper Level

Best practice in the management of STIs

Chair: Dr Sharon Hillier
University of Pittsburgh, USA

It’s in the SAC!
Dr Dave Persing
Cepheid

Using the GeneXpert system to improve clinical outcomes in men with NGU
Dr Paddy Horner
Bristol Sexual Health Clinic

Diagnosis of TV in the GUM clinic: use of T. vaginalis TMA
Dr John White
Guy’s & St Thomas’ NHS Foundation Trust, London

Debate: Trichomonas vaginalis: The hidden epidemic
Dr Paddy Horner
Bristol Sexual Health Clinic

Dr Alan McOwan
Chelsea and Westminster Hospital, London

Dr Dave Persing
Cepheid

Dr John White
Guy’s & St Thomas’ NHS Foundation Trust, London

1355–1455  Janssen Lunchtime Workshop Room 4A, Upper Level

Maximising the engagement of every patient: the key to improved outcomes in HIV?

A case study based, interactive workshop

Chair: Dr Andrew de Burgh-Thomas
Gloucester Royal Hospital

Professor Fiona Mulcahy
St James’s Hospital, Dublin, Ireland

Mr Shaun Watson
HIV Community Westminster, London

Ms Silvia Petretti
Positively UK
SATELLITE SYMPOSIA
SEMINARS AND WORKSHOPS

FRIDAY 4 APRIL 2014

All satellite symposia will be held in Hall 1A, Upper Level
Locations of workshops and evening seminars are listed below adjacent to the respective events

0900–1000

Bristol-Myers Squibb Pharmaceuticals Satellite Symposium
Treating today for tomorrow: What you need to know about managing HIV co-morbidities

Chair: Dr Ashish Sukthankar
Manchester Royal Infirmary

Dr Paddy Mallon
Mater Misericordiae University Hospital, Dublin, Ireland

Dr Marta Boffito
Chelsea and Westminster Hospital, London

1325–1425

Gilead Sciences Lunchtime Workshop Room 4A, Upper Level
Positive conversations

Chair: Dr Alan Winston
Imperial College Healthcare NHS Trust, London

Mr Allan Anderson
Positively UK

Ms Michelle Croston
North Manchester General Hospital

Ms Maureen Ndawana
African Health Policy Network

Dr Jenny Petrak
Homerton University Hospital, London

1325–1425

ViiV Healthcare Lunchtime Workshop Room 4B, Upper Level
The different faces of people living with HIV

Chairs: Mr Robert Fieldhouse
Baseline

Dr Karen Rogstad
Sheffield Teaching Hospitals NHS Foundation Trust

Five people living with HIV will be speaking as part of this workshop
EXHIBITION FLOOR PLAN
AND EXHIBITORS

Hall 2 Lower Level, Arena and Convention Centre Liverpool

EXHIBITORS

1. Birmingham HIV Partnership
2. Pregnancy Advisory Services
3. AbbVie Ltd
4. Centre for All Families Positive Health (CAFPH)
5. SAGE Publications
6. Children's HIV Association (CHIVA)
7. Boehringer Ingelheim
8. Dietitians Working in HIV / AIDS (DHIVA) / Rehabilitation in HIV Association (RHIVA)
9. BD Diagnostic Systems
10. HIV iBase / UK Community Advisory Board (UK-CAB)
11. Cepheid
12. HIV Pharmacy Association (HIVPA)
13. Merz Pharma UK
14. National AIDS Trust
15. Hologic
16. Alere
17. National HIV Nurses Association (NHIVNA)
18. Public Health England
19. BBI Healthcare
20. Atlas
21. Terrence Higgins Trust
22. 6PM Plc
23. Blithe Computer Systems
24. MSD Ltd
25. Takeda
26. Saving Lives
27. AxSys Technologies
28. Sahir House
29. ViV Healthcare UK
30. Mildmay Mission Hospital
31. National Institute for Health Research
32. Wiley Blackwell
33. Janssen Medical
34. Janssen
35. Bristol-Myers Squibb Pharmaceuticals
36. Halve-It
37. Bristol-Myers Squibb Partnering for Cure
38. African Health Policy Network (AHPN) / The Sophia Forum
39. Positively UK
40. Gilead Sciences
41. Gilead Sciences HCV
42. Baseline
CONFERENCE INFORMATION

Arena and Convention Centre Liverpool
Kings Dock · Liverpool Waterfront · Liverpool · Merseyside L3 4FP
Telephone: +44 (0)151 475 8888 · Email: info@accliverpool.com · Web: www.accliverpool.com

Registration
Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence. A delegate pack will be provided as part of your registration. Delegate packs have been sponsored by Sage Publications. 📚 SAGE

Delegate badges
Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas. The delegate lanyards have been sponsored by Gilead Sciences. 🍀 GILEAD

Accompanying persons Pre-booked and paid only
Accompanying persons’ fees include attendance at the Welcome Reception Civic Reception and Gala Dinner. Each event is individually priced. These tickets must have been requested and paid for in advance of the conference. Please note that these fees do not cover attendance at the scientific sessions, exhibition or catering areas of the conference.

BHIVA / BASHH Lunchtime workshops
Places are limited and will be restricted (80 delegates per workshop and 40 persons per skills workshop). One workshop each day will be held in the main lecture theatre (Hall 1A) and places will not be restricted to attend this session. In this way, it is anticipated that each delegate will be able to attend a minimum of one lunchtime workshop, each day, at conference, if they so wish. Places at each workshop will be available onsite, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop. Each workshop will begin promptly and lunch packs will be provided for delegates attending these sessions, where indicated. Those delegates attending the Lunchtime workshop, held in the lecture theatre will need to collect their lunch in the exhibition hall following the conclusion of the workshop, during the second hour of the lunch period.

BHIVA / BASHH Workshops supported by travel bursary grants
Sessions supported by means of an educational grant kindly donated by BHIVA / BASHH sponsors are administered by BHIVA / BASHH. All correspondence and liaison with the speakers invited to participate in these sessions has been conducted by BHIVA / BASHH and the speakers are under no obligation to the sponsoring company. Donated bursaries will go towards supporting the honorarium, travel and accommodation of invited conference speakers. The slots are entirely educational in content and form part of the BHIVA / BASHH plenary programme, and thus qualify for CPD accreditation.

BHIVA / BASHH New Consultants Forum
The BHIVA / BASHH New Consultants Forum will bring together new UK consultants (first 5 years of substantive consultant post, to include those in early locum post and/or those within 6 months of CCT) to discuss topics of mutual interest, to raise issues of concern and to provide feedback on these matters to the BHIVA / BASHH Executive Committee. The Forum will run from 1330–1600 on Tuesday 1 April 2014. Those delegates attending sessions can register for a dinner to be held in the evening following the BHIVA / BASHH Welcome Reception. Sessions comprise four forums, each devoted to a specific theme or topic. Places are limited and in principle have been made available on a first-come, first-served basis.

Continuing Professional Development (CPD)
Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 87191. The entire conference has been allocated 18 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.
CONFERENCE INFORMATION

Social events
There are three social events: a Welcome Reception (Tuesday) to be held at the Arena and Convention Centre Liverpool, a Civic Reception (Wednesday) to be held at Matou Restaurant and a Gala Dinner (Thursday) to be held at St George's Hall. You will require a ticket to gain entry to the Gala Dinner. Please refer to page 30 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.

Poster presentations
All poster boards will be numbered and poster presenters should use the board displaying the number allocated to their poster. There will be three poster sessions, held each day at lunchtime, Wednesday to Friday. All poster presenters should be available by their poster for the final 30 minutes of the Wednesday and Thursday lunchtime sessions for potential discussion with delegates and poster judges. The poster judges will review the posters and subsequently select 15 posters to be highly commended, from which six will be presented as part of the Oral Research Poster Presentations session at 1200–1230 on Friday 4 April. Poster presenters are required to prepare a few slides prior to the conference to highlight the main points of their poster. We would encourage all poster presenters to check the Registration notice board at 1700 on Thursday 3 April to see whether they have been selected. The BHIVA Ian Williams / BASHH Best Poster prize will be awarded at the Prizes and Awards Ceremony on Friday 4 April at 1430–1445.

Oral research presentations
Oral research presenters are reminded to ensure they bring their oral research presentation slides to the conference in addition to sending them to the Conference Organisers in advance. Any slides must be passed to the audio-visual technicians in the Speakers’ Preview Room located in Hall 3 Foyer in good time for their session (minimum 3 hours in advance). Oral research presenters may make use of the Speakers’ Preview Room to review their slides prior to presentation. The BHIVA Margaret Johnson / BASHH Best Oral Presentation prize will be awarded at the Prizes and Awards Ceremony on Friday 4 April at 1430–1445.

Accommodation
Please note that the registration fee does not include accommodation. If you have not already arranged accommodation you can do so by referring to the conference website for further details. It is very important to book accommodation early as rates will increase significantly nearer the time of conference, especially as the conference dates immediately precede the Grand National on the Saturday.

WiFi and internet café
Free WiFi access will be available at the conference centre in Hall 2 (exhibition hall).

Cloakroom
A manned cloakroom is available onsite on the ground level at the Arena and Convention Centre Liverpool. Items can be deposited each day at £1 per item. All belongings are left at the owner’s risk. The British HIV Association and the British Association for Sexual Health and HIV do not accept responsibility for the loss of, or damage to, delegates’ personal property stored in the cloakroom area.

Exhibition
The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

Filming and photography
Please note that all sessions held in the lecture theatre (Hall 1A) will be filmed and uploaded to the BHIVA / BASHH websites following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published either in BHIVA or BASHH publications or on the BHIVA and BASHH websites.
SCHOLARSHIPS AND AWARDS

The BHIVA Margaret Johnson / BASHH Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA / BASHH-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

The BHIVA Ian Williams / BASHH Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA / BASHH-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

The BHIVA / BASHH Best Abstract Presentation from an Undergraduate

The prize will be awarded for the best oral or poster research presentation during the conference presented by an undergraduate student. All oral and poster research presentations will be judged by a BHIVA / BASHH-appointed research judging panel. The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

The BHIVA / BASHH Maggie Godley Memorial Prize

This prize will be awarded for the best oral or poster research presentation during the conference presented by a doctor of consultant status (at the time of submission of their abstract on 17 January 2014) who works in a district general non-teaching hospital, in the UK. All oral and poster research presentations will be judged by a BHIVA / BASHH-appointed judging panel. The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

The BHIVA / BASHH Best SpR Case Presentation

A prize will be awarded to the presenter of the best case presentation as part of the BHIVA / BASHH Lunchtime Clinico-Pathological SpR Case Presentations Session and the Pregnancy, Breastfeeding and HIV Case Presentations Session. The prizes will be presented at the Prizes and Awards Ceremony on Friday 4 April.

Commended Oral Presentations

Up to three awards will be presented in recognition of the best oral research presentations during the conference. To be eligible for these prizes the presenter must be of junior grade (sub-consultant or equivalent). All oral presentations will be judged by a BHIVA / BASHH-appointed oral research judging panel. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 4 April.

Commended Poster Presentations

Up to 15 awards will be presented in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA / BASHH-appointed poster research judging panel. The prizes will be awarded at the end of Thursday 3 April. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 4 April.

Mediscript Awards in collaboration with BHIVA / BASHH

Two prizes will be awarded for the best oral or poster research presentation during the conference in the field of social sciences and community-based work. The awards will be presented at the Prizes and Awards Ceremony on Friday 4 April.

BHIVA / BASHH Science Scholarships

Science Scholarships have been awarded to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees, a contribution towards travel expenses and accommodation costs are paid by BHIVA / BASHH to successful candidates.

BHIVA Community Registrations and Scholarships

Community Scholarships have been awarded to 10 UK-based community registrants to assist them to attend the conference. For those applicants selected, all registration fees and a contribution towards expenses and accommodation costs are paid by BHIVA / BASHH. In addition, BHIVA / BASHH has supported free registration for over 40 community representatives to attend the conference.

BHIVA Registration Scholarships

Registration Scholarships have been awarded to up to 10 delegates who are either healthcare professionals who are retired, not working, or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or postgraduate work. The scholarship covers the conference registration fee.

BHIVA / BASHH Registration Support for Educational, Community and Affiliated Organisations

BHIVA/BASHH has provided reduced-cost registration places to over 20 delegates from educational, community and affiliated organisations in order to assist them with exhibiting at the conference.
SOCIAL EVENTS

Welcome Reception

Arena and Convention Centre Liverpool
Tuesday 1 April 2014: 1930–2030

ACC Liverpool is a uniquely flexible venue, the only directly interconnected arena and convention centre in Europe. ACC Liverpool opened its doors for the first time as the city celebrated European Capital of Culture. Since this time a string of accolades have followed, including CONFEX’s coveted ‘Best UK Venue’ for two consecutive years, ‘Best Corporate Social Responsibility Initiative’ and ‘Most Effective Team’ at the Exhibition News awards. The venue has hosted international events ranging from the MTV Europe Music Awards and the British Council of Shopping Centres’ annual conference to the BBC Sports Personality of the Year.

The Welcome Reception will begin with some short speeches in the lecture theatre (Hall 1A) followed by an opportunity for delegates to network in the exhibition area whilst enjoying a drink and some light refreshments.

Civic Reception

Matou Restaurant
Wednesday 2 April 2014: 1915–2030

Matou is a modern pan Asian restaurant, cocktail bar and lounge. It is located in a privileged position overlooking the vibrant dock waterfront area of Liverpool, and one of the city’s renowned landmarks, the Pier Head. Matou provides a unique experience in dining merging dishes from the Far East including Malaysia, Thailand, Singapore, Japan, China.

We are honoured that the Lord Mayor of the City of Liverpool, Councillor Gary Miller, has kindly agreed to speak as part of our Civic Reception at this prestigious venue. The event will begin with a drinks and canapé reception.

Gala Dinner

St George’s Hall
Thursday 3 April 2014: 2000–0030

St George’s Hall is one of the best examples of neo-classical buildings in the world. The impressive Great Hall with its chandeliers, stained glass windows, barrel vaulted ceiling and world-famous Willis Organ make this venue the perfect city centre location for our Gala Dinner.

The Gala Dinner will commence with a drinks reception followed by dinner at St George’s Hall. After some short speeches, entertainment will include music by The Toni James Band. The band is an eight-piece ensemble that pride themselves on delivering an energetic and super slick performance that will have everybody up dancing.
Achieve same-day detection and containment with Xpert CT/NG. In addition to single-test confidence for CT/NG, our full menu of fast, accurate and easy-to-use molecular tests helps you strengthen antibiotic stewardship, shrink patient stays, advance care, and reduce costs. Welcome to immediate informed decisions.

Cepheid powers same-day results in more than 5,000 locations worldwide. Learn more at cepheidinternational.com.
BIOGRAPHIES

Jane Anderson (Homerton University Hospital NHS Foundation Trust and Public Health England) has been involved in the care of people with HIV since the beginning of the epidemic. Her clinical practice and research focus on the prevention, treatment and care of HIV amongst migrant and ethnic minority populations in the UK. She holds honorary professorial appointments at Queen Mary, University of London and University College London. She is immediate past Chair of the British HIV Association and is an adviser to Public Health England on HIV, sexual and reproductive health matters.

Vanessa Apea is a Consultant in GU/HIV Medicine at Barts Health NHS Trust. Her clinical and research interests are in the provision of sexual health and HIV care for marginalised groups, community outreach and global health service delivery. She is the lead for the management of those hard to engage in care at the Grahame Hayton Unit. She is also the BASHH North Thames Audit Chair.

David Asboe is a Consultant in HIV Medicine and Sexual Health at Chelsea and Westminster Hospital. He studied medicine at Otago University Medical School, New Zealand and completed specialist training at St Thomas’ Hospital London. He is Divisional Research Lead and his research interests are antiretroviral resistance and the sexual health of people living with HIV. He is the Convenor of the Diploma in HIV Medicine, and is a Trustee on the Executive Committee of the British HIV Association. He was elected as BHIVA Chair in 2013.

Dola Awoyemi is an HIV/GUM specialist pharmacist at Kingston Hospital NHS Foundation Trust. She has an interest in public health programmes in developing countries and is currently completing a Masters in Public Health, health service management stream at the London School of Hygiene and Tropical Medicine.

Abdel Babiker is a Scientific Programme Leader at the MRC Clinical Trials Unit and a Professor of Epidemiology and Medical Statistics at UCL. He has worked for many years on the development and implementation of clinical trials in HIV and other infections including more recently the SPARTAC and NEAT 001 trials. He currently co-chairs the START trial, conducted by the INSIGHT network, and sits on the WHO/TDR Advisory Committee on Research in Integrated Community Case Management of Childhood Illness.

David Back is a Professor of Pharmacology at the University of Liverpool and has worked in the area of Pharmacokinetics and drug–drug interactions for more than 35 years. He established the Liverpool HIV Pharmacology Group (LHPG) in 1987 and subsequently the Liverpool group has been at the forefront of pharmacological research of anti-infective drugs. Currently there are numerous ongoing pharmacokinetic, pharmacogenetic and molecular- based studies involving local, national and international collaborations. David has authored ~400 publications. He is a former Editor of the British Journal of Clinical Pharmacology and is on the Editorial Board of numerous journals. He has established several key resources for health care professionals including www.hiv-druginteractions.org and www.hep-druginteractions.org. In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for Outstanding Contribution to Clinical Pharmacology.

Ravneet Batra is a Consultant Liaison Psychiatrist with special interest in blood-borne viruses and is based full time at the Regional Infectious Diseases Unit in Edinburgh. Ravneet is involved in the policy guidelines and all aspects of delivery of care for mental health problems associated with bloodborne viruses and its treatments.

Mas Chaponda is a Consultant Physician in HIV Medicine within the subdirectorate of Infectious Diseases and Clinical Pharmacology, Royal Liverpool University Hospitals NHS Trust. The position combines the expertise of the Tropical Infectious Diseases Unit, HIV Pharmacology and the Liverpool Centre for Sexual Health. In addition, Dr Chaponda is a key figure in the Cheshire, Mersey and North Wales HIV clinical network. Dr Chaponda is a BHIVA Executive Committee member as well as a Clinical Representative on the National HIV Clinical Reference Group (CRG). His interests include HIV drug interactions, TB and clinical trials.

Jan Clarke is a Consultant in Genitourinary Medicine at the Leeds Teaching Hospitals Trust. A former Treasurer and General Secretary of BASHH, she has chaired the Public and Patient Engagement group for the past 2 years. Her professional interests include adolescent and paediatric aspects of GU medicine, mentoring for clinicians, and partner notification for STIs.
BIOGRAPHIES

James Coutts trained at Oxford University Medical School, with medical qualification in 1989. He became a member of the Royal College of Physicians by examination in 1992, and subsequently a fellow in 2006. After training in general medicine he undertook three years’ training in Intensive care, before specialising in cardiology. He was appointed consultant cardiologist at Guy’s and St Thomas’ Hospitals in 2002. He has a specialist interest in coronary intervention (angiography and angioplasty for ischaemic heart disease), in addition to working in general cardiology and general medicine.

Subathira Dakshina is a Specialist Registrar (ST4) in HIV and Sexual Health at Royal London Hospital, Barts Health NHS Trust.

Annemiek de Ruiter is a Consultant Physician in HIV/GUM at St Thomas’ Hospital, London and has managed HIV-positive patients for over 20 years, specialising in the management of pregnant women with HIV. She has published extensively, formed local and national networks, collaborated widely, advised at a national level, lectured nationally and internationally, and led the development of the BHIVA 2012 and 2014 Pregnancy guidelines. She is the BHIVA Honorary Secretary and sits on the BHIVA Conferences and Guidelines subcommittees.

Carol Emerson is a Consultant in HIV/GUM in Belfast. She is currently the Co-chair of the BASHH & BHIVA Mentoring Group and sits on the BHIVA Conferences Subcommittee. As the past new consultant BHIVA representative she worked hard on the BHIVA Executive Committee for recently appointed consultants and set up the new consultant forum.

Dr Claudia Estcourt is Reader in Sexual Health and HIV at Barts and The London School of Medicine and Dentistry, and Consultant at Barts Health NHS Trust. Her major research interests focus on public health and health service interventions to control STIs, latterly focusing on methods of improving partner notification, and near-patient STI diagnostics and remote web-based STI management. Other strands of work include web-based safer sex interventions, and development of new tests for whole genome sequencing of STI pathogens. She is enthusiastic about multidisciplinary clinical skills learning & teaching both in the UK and in developing countries, whilst clinically, she focuses on complex female sexual health and outpatient HIV medicine in East London.

Christopher Fairley is Director of Melbourne Sexual Health Centre and Professor of Public Health at Monash University. His main research interests are the clinical and public health aspects of the control of sexually transmitted infections.

Kate Folkard is National Chlamydia Screening Programme Manager at Public Health England. She is also managing work that PHE is leading on the development of a framework for whole system approach to commissioning of HIV, sexual and reproductive health services. Kate was previously a sexual health commissioner in a PCT and has extensive experience across local and national government, health and third sector.

Emma Fox is a Consultant in Genitourinary/HIV Medicine in Kent Community Health Trust, having previously held consultant posts at St George’s Hospital and Guy’s and St Thomas’ Hospitals. She was a founding member of the BASHH Mentoring Group and is currently Co-chair of the BASHH/BHIVA Mentoring Group.

Linda Furness is a Senior Sexual Health Adviser at Cardiff Royal Infirmary Department of GUM and the SSHA NPC Welsh representative.

Brian Gazzard started the HIV unit at the Chelsea and Westminster Hospital and is now its Clinical Research Director. This is one of the largest clinical units in Europe, concentrating its research mainly on new algorithms of care, immunological and oncolgical manifestations of HIV disease and antiretroviral therapy. Brian Gazzard qualified at Cambridge and received his MD from that institution in 1983. He was awarded the Department of Health prize for distinguished achievement in 2002 and is the Chairman of the Expert Group Advising Chief Medical Officer of Health on matters relating to HIV disease.

Anna Maria Geretti is Professor of Virology & Infectious Diseases at the Institute of Infection & Global Health, University of Liverpool. Anna Maria’s clinical and research activities focus on HIV and viral hepatitis, with a specific interest in antiviral therapy, virus genetic diversity, and diagnostics, and she has over 100 publications. She contributes to national and international management guidelines, is Secretary of EACS, and founding member of the British Society for NanoMedicine. Anna Maria runs programmes in resource-limited settings and enthusiastically shares her expertise to train doctors and scientists.
Dame Anne Johnson is Professor of Infectious Disease Epidemiology at University College London and Honorary Public Health Consultant at Central and North West London NHS Foundation Trust. She has been Principal Investigator on the National Survey for Sexual Attitudes and Lifestyles 1990, 2000 and 2010, and is a Governor of the Welcome Trust.

Saye Khoo is an Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the School of Biomedical Sciences at the University of Liverpool. His research focuses on the pharmacology of HIV treatment failure and how therapy may be improved by individualised care through understanding why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics and drug interactions), and identifying vulnerable groups who are at particular risk of failure, or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population-based modelling approaches.

Mark Lawton is a Consultant in Sexual Health & HIV in Liverpool. His interests include HPV and the sexual health needs of MSM. He is delighted to be co-facilitating the workshop on ‘legal responses to HIV & other STIs’ with Professor Weait – a complex but important topic.

Sebastian Lucas has worked on the pathology of HIV/AIDS since 1982, and continues in part-retirement (but still based at St Thomas’ Hospital). His interests are the clinico-pathological correlation of HIV disease, diagnostics of opportunistic diseases, the direct pathology induced by HIV, and the complications of cART and of increasing age in HIV-infected persons.

Fiona Lyons is a Consultant in GU/HIV Medicine at the GUIDE clinic, St James’s Hospital, Dublin, Ireland, where she is Joint Clinical Lead for HIV in Pregnancy. Her special interests include HIV infection in women and in pregnancy. She is joint author of the Irish Guidelines for the Management of HIV in Pregnancy and has acted as an external assessor for the BHIVA HIV in Pregnancy guidelines.

Alan McOwan has a particular interest in early diagnosis and reduction of undiagnosed HIV in MSM. He introduced the UK’s first NHS HIV point-of-care testing services in 2002. The testing projects he has developed now diagnose 1 in 6 of the UK’s new HIV in MSM. Alan has pioneered the use of social media to offer home HIV sampling to high-risk MSM. This innovative model of care won the 2013 BMJ Award for ‘Transforming Healthcare Using Technology’.

Christina Marra completed residency training in Neurology and fellowship training in Infectious Diseases. She is Professor of Neurology with an adjunct appointment in Medicine (Infectious Diseases) at the University of Washington in Seattle, Washington, USA. She directs a research program on neurosyphilis, participates in multi-centre clinical research on the neurological consequences of HIV and provides neurological care in a multispecialty HIV clinic.

Anatole Menon-Johansson is the Clinical Lead for Sexual Health at Guy’s & St Thomas’ NHS Foundation Trust that includes the seven-day-a-week Burrell Street Sexual Health Clinic (www.burrellstreet.co.uk), the Clinical Director of the charity Brook (www.brook.org.uk) and founder of the sexual health information and real time sign posting service SXT (www.sxt.org.uk).

Eileen Nixon has been a Nurse Consultant in HIV since 2004. She has served on the NHIVNA Executive Committee and was co-author of the National HIV Nursing Competencies. Eileen has just completed a PhD exploring HIV models of care and she currently represents NHIVNA members on the HIV Clinical Reference Group.

Nick Paton is an Infectious Diseases Physician and Clinical Researcher. His research interests are in therapeutic clinical trials for HIV and TB, particularly of interventions that are relevant to resource-limited settings. In 2011, he took up a Chair of Infectious Diseases at the National University of Singapore, where he leads a programme of TB translational research and trials. He continues involvement with the MRC Clinical Trials Unit as the Chief Investigator on the PIVOT and EARNEST trials.
BIOGRAPHIES

Massimo Puoti is a Specialist in Infectious Diseases and Gastroenterology with a particular interest in hepatitis and HIV infection. He is the Director of the Infectious Diseases Department in the largest hospital in Milan, the AO Niguarda Ca’ Granda.

Michael Rayment is currently a Locum Consultant in Sexual Health and HIV Medicine at Homerton University Hospital. His main clinical interest is sexual health and HIV prevention in MSM. Michael’s main research interest is the evaluation of HIV testing strategies to reduce undiagnosed and late-diagnosed HIV infection in the UK.

Andrew Riordan is a Consultant in Paediatric Infectious Diseases and Immunology at Alder Hey Children’s NHS Foundation Trust in Liverpool. He was a Committee member of the Children’s HIV Association and was the Lead Clinician for the North West Children’s HIV Network 2010–2013.

Daniel Richardson is a Consultant Physician in Sexual Health & HIV at Brighton & Sussex University Hospitals NHS Trust, and Honorary Senior Lecturer at Brighton & Sussex Medical School. He trained in GU Medicine at St Mary’s in Paddington. He is currently the BASHH Conference Secretary. Daniel’s research interests are in the sexual health of men who have sex with men.

Dana Rosenfeld is a Senior Lecturer in Sociology, Keele University and medical sociologist and social gerontologist with particular interests in ageing and the life course, HIV and ageing, and the lived experience of chronic illness and disability. She was Lead Investigator on the MRC-funded HIV and Later Life study (2011–2013).

Jonathan Ross is Professor of Sexual Health and HIV and has worked as a Consultant Physician in Sexual Health and HIV Medicine in Birmingham since 1997. He is treasurer for the British Association for Sexual Health and HIV, editor of STD Global Update and sits on the IUSTI World Executive Committee. He is also an associate editor of the journal Sexually Transmitted Infections, a member of the editorial board for European Sexually Transmitted Diseases Guidelines and Chairman of the Neurology Specialty Question Group for the MRCP examination. He is the author of UK and European Guidelines on Pelvic Inflammatory Disease and editor of the UK National Screening and Testing Guidelines for STDs. He is on the Editorial Board of the Cochrane Collaboration Sexually Transmitted Diseases Collaborative Review Group and International Journal of STD and AIDS journal. His research interests are pelvic infection, gonorrhoea, Mycoplasma genitalium, HIV and sexual health care service delivery.

Ann Sullivan trained in Australia and London, gaining an MD in HIV Immunology. She is now a Consultant at Chelsea and Westminster Hospital. Her specific interests include expanding HIV testing, MSM sexual health and utilising technology to improve patient care and experience. As a member of both BASHH and BHIVA audit groups she led the recent National HIV Partner Notification audit.

Alexandra Teleka graduated from the University of Malawi in 2010 with a Bachelor of Medicine and Surgery. She worked at Kamuzu Central Hospital for 2 years and is currently working as District Medical Officer at Blantyre District Health Office.

Analia Urena is an Infectious Diseases Specialist and staff member at Helios Salud, which is a private ambulatory care centre for HIV-infected people in Argentina. She is also a medical staff member of the National Programme for the Control of Vaccine-Preventable Diseases of the Ministry of Health in Buenos Aires, Argentina.

Andrew Ustianowski is a Consultant Physician in Infectious Diseases & Tropical Medicine, and Clinical Director, at the Monsall Regional Infection Unit, North Manchester General Hospital, which has a cohort of over 2000 HIV-positive patients. He is also chair of the British Viral Hepatitis Group, represents on the Clinical Reference Group for Infectious Diseases, is part of guideline writing committees for BHIVA and other bodies, lectures widely on HIV, hepatitis and related topics, and is involved in several educational steering groups.

Laura Waters is a GU/HIV Consultant at the Mortimer Market Centre, London, working in HIV and hepatitis outpatient and HIV inpatient services. She completed specialist training in 2006 then worked in clinical trials at Chelsea & Westminster and Brighton, completing an MD on the simplification and switch of antiretrovirals. She has published and presented widely on topics including drug toxicity and contraception for HIV-positive women. She is chair of the BASHH HIV special interest group and is Vice Chair of the BHIVA Guidelines Subcommittee.
BIOGRAPHIES

Matthew Weait is Professor of Law and Policy and Pro-Vice-Master at Birkbeck, University of London. He was a member of the Technical Advisory Group for the Global Commission on HIV and the Law, and an advisor to the European AIDS Treatment Group. Matthew was the legal and ethics advisor for the PARTNER study, and has published widely on the criminalisation of HIV.

Jonathan Weber is the Jefferiss Professor of Communicable Diseases and GU Medicine at Imperial College London. He has researched HIV vaccines since 1990: as PI for the first UK HIV vaccine study in 1991 (Ty.VLP); the MRC/SK-B rgp120 (W61D) programme; the EuroVacc on DNA-NYVAC studies; and currently the Wellcome Trust UK HIV Vaccine Consortium developing DNA-prime, modified poxvirus boost, protein/adjuvant re-boost strategies.

John White is an Australian Sexual Health Physician who has been working in the UK since 2004 as a Consultant Physician in the Department of Genitourinary Medicine at Guy’s and St Thomas’ Hospitals in London. His professional interests include bacterial STIs, sexual health of men who have sex with men (MSM) and diagnostic tests for HIV/STIs. He has a keen interest in lymphogranuloma venereum infection in MSM and is involved in several research studies involving the assessment of diagnostic tests for bacterial STIs and HIV. He is Chair of the British Association of Sexual Health & HIV Education Committee and also sits on the Core Group of the European Collaborative Clinical Group of the International Union against Sexually Transmitted Infections (IUSTI). Since 2009 he has been Editor-in-Chief of the International Journal of STD & AIDS.

Janet Wilson is a Consultant in Sexual Health and HIV in Leeds and is the Past-President of BASHH. As President she wrote to all Local Authority CEOs about the potential problems associated with tendering of sexual health services. She was a member of the group producing the BASHH National Standards for the Management of STIs 2014. Her main areas of research interest are the application and cost-effectiveness of diagnostic tests; infections in pregnancy (including HIV); and recurrent vaginal infections.

Adam Winstock is a Consultant Addiction Psychiatrist at the South London and Maudsley NHS Trust and Senior Lecturer at the Institute of Psychiatry. He has written over 100 papers and book chapters. He is also founder of Global Drug Survey which runs the world’s biggest drug survey and developer of the online and smartphone apps the drugsmeter (www.drugsmeter.com) and drinksmeter (www.drinksmeter.com).
## SPONSORS AND EXHIBITORS

### CONFERENCE SPONSORS

<table>
<thead>
<tr>
<th>Sponsor Name</th>
<th>Address</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Ltd</td>
<td>Abbott House, Vanwall Business Park, Maidenhead, Berkshire SL6 4XE</td>
<td><img src="abbove.png" alt="AbbVie" /></td>
</tr>
<tr>
<td>BD Diagnostics</td>
<td>The Danby Building, Edmund Halley Road, Oxford Science Park, Oxford OX4 4DQ</td>
<td><img src="BD.png" alt="BD" /></td>
</tr>
<tr>
<td>Boehringer Ingelheim Ltd</td>
<td>Ellesfield Avenue, Bracknell, Berkshire RG12 8YS</td>
<td><img src="Boehringer.png" alt="Boehringer Ingelheim" /></td>
</tr>
<tr>
<td>Bristol-Myers Squibb Pharmaceuticals Ltd</td>
<td>Uxbridge Business Park, Sanderson Road, Middlesex UB8 1DH</td>
<td><img src="Bristol.png" alt="Bristol-Myers Squibb" /></td>
</tr>
<tr>
<td>Cepheid UK Limited</td>
<td>Jupiter House, Mercury Park, Wooburn Green, Buckinghamshire HP10 0HH</td>
<td><img src="Cepheid.png" alt="Cepheid" /></td>
</tr>
<tr>
<td>Gilead Sciences Ltd</td>
<td>Granta Park, Great Abington, Cambridgeshire CB21 6GT</td>
<td><img src="Gilead.png" alt="Gilead" /></td>
</tr>
<tr>
<td>MSD Ltd</td>
<td>Hertford Road, Hoddesdon, Hertfordshire EN11 9BU</td>
<td><img src="MSD.png" alt="MSD" /></td>
</tr>
<tr>
<td>Janssen</td>
<td>50–100 Holmers Farm Way, High Wycombe, Buckinghamshire HP12 4DP</td>
<td><img src="Janssen.png" alt="Janssen" /></td>
</tr>
<tr>
<td>ViiV Healthcare UK Ltd</td>
<td>Stockley Park West, Uxbridge, Middlesex UB11 1BT</td>
<td><img src="ViiV.png" alt="ViiV Healthcare" /></td>
</tr>
</tbody>
</table>

### CONFERENCE EXHIBITORS

#### Pharmaceutical and Commercial

<table>
<thead>
<tr>
<th>Sponsor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>6PM Plc</td>
</tr>
<tr>
<td>Alere</td>
</tr>
<tr>
<td>Atlas</td>
</tr>
<tr>
<td>AxSys Technologies</td>
</tr>
<tr>
<td>BBI Healthcare</td>
</tr>
<tr>
<td>Blithe Computer Systems</td>
</tr>
<tr>
<td>Hologic</td>
</tr>
<tr>
<td>Merz Pharma UK</td>
</tr>
<tr>
<td>Pregnancy Advisory Services</td>
</tr>
<tr>
<td>Takeda</td>
</tr>
</tbody>
</table>

#### Affiliated, Educational and Charitable

<table>
<thead>
<tr>
<th>Sponsor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birmingham HIV Partnership</td>
</tr>
<tr>
<td>Children’s HIV Association (CHIVA)</td>
</tr>
<tr>
<td>Dietitians Working in HIV/AIDS DHIVA</td>
</tr>
<tr>
<td>Halve It</td>
</tr>
<tr>
<td>HIV Pharmacy Association (HIVPA)</td>
</tr>
<tr>
<td>Mildmay Mission Hospital</td>
</tr>
<tr>
<td>National HIV Nurses Association (NHIVNA)</td>
</tr>
<tr>
<td>National Institute of Health Research (NIHR)</td>
</tr>
<tr>
<td>Public Health England</td>
</tr>
<tr>
<td>Rehabilitation in HIV Association (RHIVA)</td>
</tr>
<tr>
<td>SAGE Publications</td>
</tr>
<tr>
<td>Saving Lives</td>
</tr>
<tr>
<td>Wiley Blackwell</td>
</tr>
</tbody>
</table>

#### Community

<table>
<thead>
<tr>
<th>Sponsor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>African Health Policy Network (AHPN)</td>
</tr>
<tr>
<td>Baseline</td>
</tr>
<tr>
<td>Centre for All Families Positive Health (CAFPH)</td>
</tr>
<tr>
<td>HIV i-Base</td>
</tr>
<tr>
<td>UK Community Advisory Board (UK-CAB)</td>
</tr>
<tr>
<td>National AIDS Trust (NAT)</td>
</tr>
<tr>
<td>Positively UK</td>
</tr>
<tr>
<td>Terence Higgins Trust</td>
</tr>
<tr>
<td>The Sophia Forum</td>
</tr>
<tr>
<td>Sahir House</td>
</tr>
</tbody>
</table>
HIV Select

a comprehensive HIV services toolkit developed by Janssen, for now and for the future.

HIV Select was developed following research into the unmet needs of health care professionals and patients, with input from a steering group of HIV specialists. The toolkit provides information on Janssen products, tools for patient care and case management, and resources to support healthcare providers throughout their patient’s journey. Janssen is dedicated to providing new services to HCPs and Patients. We hope that you find this toolkit useful.

**Efficiency Tools**
- Case Management
- Integrated Care Pathway
- HIV Database and HARS Collection Tool
- Service Redesign Model

**Patient Tools**
- Adherence Kit

**Health Care Professional tools**
- Medical Scholarships
- Medical Education
- Patient Portraits, case study based meetings developed by clinicians for clinicians
- T3 - Think, Talk, Test an anti-stigma campaign

For more information please contact your local Janssen Account Manager.
Introducing a reason to rethink first-line treatment in HIV.

- Rapid and sustained efficacy through to 96 weeks
- High barrier to resistance
- Generally well tolerated with few discontinuations
- Once daily with few DDIs or dosing restrictions

*Tivicay* is dosed 50 mg once daily for patients without documented or clinically suspected resistance to the integrase class. *Tivicay* should be dosed 50 mg once daily in patients with resistance to the integrase class (documented or clinically suspected) or in patients taking certain concomitant medicines (e.g., efavirenz, nevirapine, tipranavir/ritonavir).6

**Presentation:**

50mg film-coated tablets of dolutegravir.

**Indications:**

Treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age in combination with other antiretroviral medicinal products. Dosage and administration: For use by physicians experienced in management of HIV infection. Adults infected with HIV-1 without documented or clinically suspected resistance to the integrase class (documented or clinically suspected): 50mg twice daily, preferably with food to enhance exposure (particularly in patients with Q148 mutations). Dolutegravir use should be informed by integrase resistance pattern. The recommended dose of Tivicay is 50mg twice daily when co-administered with efavirenz, nevirapine, tipranavir/ritonavir or rifampicin. Adolescents aged 12 years and above (weighing at least 40kg) without integrase resistance: 50mg once daily with or without food. Children less than 12 years of age weighing <40kg, insufficient data to recommend a dose. Elderly: Limited data in patients over 65 years of age. Renal impairment: No dosage adjustment required in mild, moderate or severe (CrCl<30ml/min, not on dialysis) renal impairment. Hepatic impairment: No dosage adjustment required in mild or moderate hepatic impairment. No data in severe hepatic impairment.

**Contraindications:**

Hypersensitivity to dolutegravir or to any of the excipients.

Co-administration with dolutistic. Warnings and precautions: Hypersensitivity reactions have been reported characterised by rash, constitutional findings, and organ dysfunction, including severe liver reactions. Discontinue dolutegravir and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop. Delay in stopping treatment may result in a lifethreatening reaction. Monitor clinical status including liver aminotransferases and bilirubin. Institution of combination antiretroviral therapy may result in an inflammatory reaction to asymptomatic or residual opportunistic pathogens and cause serious clinical conditions, or aggravation of symptoms. Liver biochemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis B and/or C co-infected patients at the start of dolutegravir therapy. Monitoring of liver biochemistries in hepatitis B and/or C co-infection is recommended. Initiate or maintain effective hepatitis B therapy when starting dolutegravir in hepatitis B co-infection. Osteonecrosis has been reported, particularly with acknowledged risk factors, advanced HIV disease or long-term combined antiretroviral exposure. Avoid factors that decrease dolutegravir exposure in the presence of integrase class resistance, including co-administration with medicinal products that reduce dolutegravir exposure (e.g., magnesium/aluminum-containing antacids, iron and calcium supplements, multivitamins and inducing agents tipranavir/ritonavir, rifampicin and certain antiepileptic drugs). Careful monitoring required with concomitant meflozin.

**Interactions:**

Dolutegravir is metabolised mainly by UGT1A1. Co-administration with medicinal products inhibiting UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or Pgp may increase plasma concentration. Dolutegravir is a substrate for UGT1A3, UGT1A9, CYP3A4, Pgp, and BCRP; medicinal products inducing those enzymes may decrease dolutegravir plasma concentration and reduce its therapeutic effect. Dolutegravir may increase plasma concentrations of OCT2 dependent drugs (e.g., dofetilide, metformin). Avoid co-administration with enzyme inducers including anticonvulsants and St John’s Wort. Administer dolutegravir 2 hours before or 6 hours after magnesium/aluminum-containing antacids, calcium, iron or multivitamin supplements. Dose with 50mg twice daily when co-administered with efavirenz, nevirapine, tipranavir/ritonavir or rifampicin. Consider alternative agents to these and fosamprenavir/ritonavir where possible in integrase resistant patients. Co-administration with etravirine is not recommended unless concomitant atazanavir + ritonavir, lopinavir + ritonavir or darunavir+ritonavir are given. Pregnancy and lactation: Not recommended in pregnant women. Avoid breast-feeding. Side effects: See SPC for full details. Very common (>1/10): headache, diarrhoea, nausea. Common (>1/100 to <1/10): abnormal vision, nasoconia, insomnia, abnormal dreams, dizziness, vomiting, flushing, abdominal pain or discomfort, rash, pruritus, fatigue, elevations of ALT, AST, and CPK. Uncommon (<1/1000 to <1/100): hypersensitivity. Immune Reconstitution Syndrome. Hepatitis. Serum creatinine increases within the first week of treatment and remains stable through 48 weeks (mean change from baseline 9.96 μmol/L). Creatinine increases were comparable by background regimen. These changes do not reflect alteration in glomerular filtration rate. Basic NHS costs: £498.75 for 30 tablets (licence number: EU/1/13/892/001). Marketing authorisation holder: ViiV Healthcare UK Ltd. 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1FT.

**References:**